The European Medicines Agency has approved the generic Volibris for the EU market
Ambrisentan Mylan is a medication that is used alone or in combination with other medicines for the treatment of adults with pulmonary arterial hypertension (PAH).
Ambrisentan Mylan is used in patients with class II or III. Ambrisentan Mylan is effective for PAH without detectable cause and PAH caused by connective tissue disease.
Ambrisentan Mylan contains the active substance ambrisentan and is a “generic drug”. This means that Ambrisentan Mylan contains the same active substance and works in the same way as original medicines already authorized in the EU under the name Volibris.